Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Sep 18:S0168-8278(17)32287-0.
doi: 10.1016/j.jhep.2017.09.007. Online ahead of print.

Targets for immunotherapy of liver cancer

Tim F Greten  1 , Bruno Sangro  2
Affiliations
Review

Targets for immunotherapy of liver cancer

Tim F Greten et al. J Hepatol. .

Abstract

Drug development in hepatocellular carcinoma (HCC) has been characterised by many failures in the past. Despite good rationales and promising phase II data, many phase III trials failed. Immunotherapy represents an alternative treatment approach that has been successful in many different cancer types. As an inflammation induced cancer, HCC represents a very interesting target for immune based approaches. Indeed, early results from clinical trials testing immune checkpoint inhibitors are not only promising, but have already led to evaluation in a phase III setting. Herein, we summarise our current knowledge on the rationale, mechanism of action and clinical data for immune checkpoint blockade in HCC. In addition, we provide an overview of other novel immune based approaches currently under development for the treatment of HCC, such as adoptive cell based and antibody-based approaches.

Keywords: Cancer; HCC; Immunotherapy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

Bruno Sangro has received consulting and/or lecture fees from Adaptimmune, Astra Zeneca, Bayer Healthcare, Bristol-Myers-Squibb, Medimmune and Onxeo.

Figures

Figure 1
Figure 1
Immune based approaches in HCC
Figure 2
Figure 2
Survival following Nivolumab among patients that progressed or are intolerant to Sorafenib. The survival reported in placebo-treated arms in large clinical trials addressing the second-line advanced HCC population is presented for comparison [,,–52].
Figure 3
Figure 3
Strategies to increase the efficacy of anti-PD1/PDL1 blockade based on mechanism of action.
See this image and copyright information in PMC

References

    1. Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018. doi: 10.1038/nrdp.2016.18. - DOI - PubMed
    1. Bruix J, Qin S, Merle P, Granito A, Huang Y-H, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56–66. doi: 10.1016/S0140-6736(16)32453-9. - DOI - PubMed
    1. Greten TF, Manns MP, Korangy F. Immunotherapy of hepatocellular carcinoma. J Hepatol. 2006;45:868–78. doi: 10.1016/j.jhep.2006.09.004. - DOI - PubMed
    1. Greten TF, Manns MP, Korangy F. Immunotherapy of HCC. Rev Recent Clin Trials. 2008;3:31–9. - PubMed
    1. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy Science. 2013;342:1432–3. doi: 10.1126/science.342.6165.1432. - DOI - PubMed